bluebird bio Inc (BLUE.OQ)
BLUE.OQ on NASDAQ Stock Exchange Global Select Market
137.03USD
8:59pm GMT
137.03USD
8:59pm GMT
Change (% chg)
$2.74 (+2.04%)
$2.74 (+2.04%)
Prev Close
$134.29
$134.29
Open
$135.60
$135.60
Day's High
$137.16
$137.16
Day's Low
$134.54
$134.54
Volume
155,960
155,960
Avg. Vol
241,835
241,835
52-wk High
$236.05
$236.05
52-wk Low
$87.64
$87.64
Consensus Recommendations
| Consensus Recommendation | Next Earnings (approx.) | Company Fiscal Year End Month |
Last Updated |
|---|---|---|---|
| Outperform | -2.76 | December | 15 Feb 2019 |
Analyst Recommendations and Revisions
| 1-5 Linear Scale | Current | 1 Month Ago |
2 Month Ago |
3 Month Ago |
|---|---|---|---|---|
| (1) BUY | 9 | 9 | 8 | 7 |
| (2) OUTPERFORM | 8 | 8 | 8 | 9 |
| (3) HOLD | 7 | 7 | 7 | 6 |
| (4) UNDERPERFORM | 0 | 0 | 0 | 0 |
| (5) SELL | 0 | 0 | 0 | 0 |
| No Opinion | 0 | 0 | 0 | 0 |
| Mean Rating | 1.92 | 1.92 | 1.96 | 1.95 |
Consensus Estimates Analysis
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| # of Estimates | Mean | High | Low | 1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Mar-19 | 13 | 10.42 | 19.80 | 5.00 | 4.60 |
| Quarter Ending Jun-19 | 13 | 10.88 | 19.80 | 5.00 | 2.70 |
| Year Ending Dec-19 | 23 | 60.94 | 121.59 | 11.00 | 108.03 |
| Earnings (per share) | |||||
| Quarter Ending Mar-19 | 14 | -2.76 | -2.22 | -3.18 | -1.96 |
| Quarter Ending Jun-19 | 14 | -2.94 | -2.40 | -3.28 | -2.10 |
| Year Ending Dec-19 | 23 | -11.52 | -9.13 | -12.95 | -6.54 |
Historical Surprises
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Estimates vs Actual | Estimate | Actual | Difference | Surprise % |
|---|---|---|---|---|
| SALES (in millions) | ||||
| Quarter Ending Sep-18 | 7.51 | 11.53 | 4.02 | 53.55 |
| Quarter Ending Jun-18 | 9.64 | 7.85 | 1.79 | 18.58 |
| Quarter Ending Mar-18 | 5.60 | 15.96 | 10.36 | 185.11 |
| Quarter Ending Dec-17 | 7.06 | 4.17 | 2.89 | 40.93 |
| Quarter Ending Sep-17 | 7.07 | 7.71 | 0.64 | 9.06 |
| Earnings (per share) | ||||
| Quarter Ending Sep-18 | -2.87 | -2.73 | 0.14 | -4.88 |
| Quarter Ending Jun-18 | -2.35 | -2.91 | 0.56 | -24.01 |
| Quarter Ending Mar-18 | -2.07 | -2.31 | 0.24 | -11.70 |
| Quarter Ending Dec-17 | -1.70 | -2.52 | 0.82 | -48.14 |
| Quarter Ending Sep-17 | -1.71 | -1.73 | 0.02 | -1.38 |
Consensus Estimates Trend
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Current | 1 Week Ago |
1 Month Ago |
2 Month Ago |
1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Mar-19 | 10.42 | 10.42 | 10.42 | 10.72 | 4.60 |
| Quarter Ending Jun-19 | 10.88 | 10.88 | 10.88 | 11.22 | 2.70 |
| Year Ending Dec-19 | 60.94 | 60.94 | 63.01 | 66.20 | 108.03 |
| Earnings (per share) | |||||
| Quarter Ending Mar-19 | -2.76 | -2.76 | -2.76 | -2.79 | -1.96 |
| Quarter Ending Jun-19 | -2.94 | -2.94 | -2.94 | -2.96 | -2.10 |
| Year Ending Dec-19 | -11.52 | -11.52 | -11.43 | -11.42 | -6.54 |
Estimates Revisions Summary
| Last Week | Last 4 Weeks | |||
|---|---|---|---|---|
| Number Of Revisions: | Up | Down | Up | Down |
| Revenue | ||||
| Quarter Ending Mar-19 | 0 | 0 | 0 | 0 |
| Quarter Ending Jun-19 | 0 | 0 | 0 | 0 |
| Year Ending Dec-19 | 0 | 0 | 0 | 1 |
| Earnings | ||||
| Quarter Ending Mar-19 | 0 | 0 | 0 | 0 |
| Quarter Ending Jun-19 | 0 | 0 | 0 | 0 |
| Year Ending Dec-19 | 0 | 0 | 0 | 1 |
Earnings vs. 
Estimates- UPDATE 7-Bristol-Myers to buy Celgene for $74 bln in largest biopharma deal
- Amgen antibody shows promise in myeloma trial, gets FDA fast track
- UPDATE 1-Amgen antibody shows promise in myeloma trial, gets FDA fast track
- Amgen's AMG420 shows responses in myeloma trial, gets FDA fast track
- UPDATE 1-Rare manufacturing glitch raises concern over CAR-T therapies -study